COVID-19 Update: Information and resources can be found here.

Advancing UT Southwestern's Research to Maximize Patient Benefit

The Office for Technology Development (OTD) is designed to support and advance UT Southwestern as an elite driver of health care innovation and commercialization. The Office has been realigned to streamline efficiencies and provide a better experience for UT Southwestern researchers and its external stakeholders. Through this realignment, the Office has created six new Commercialization Success Partner (CSP) positions and two new Assistant Director of Technology Commercialization (ADC) positions to serve as OTD Liaisons to directly interact with faculty, Principal Investigators, researchers and the business development team to ensure timely, customer-focused communication and collaboration. Each CSP and/or ADC is assigned to specific departments at UT Southwestern to better serve researchers’ needs.

Download list of department assignments and connect with your OTD Liaison.

OTD is working to accelerate UT Southwestern technologies through the commercialization process in order to maximize their societal impact. Our team looks forward to working with you all as the we continue to transition to better meet the needs of the increasingly complex research, technology development, and commercialization relationship that are required to advance UT Southwestern’s innovative science into therapies that directly benefit patients.

Current Events

TMC | ACT Accelerator Program for Cancer Therapeutics - Program Extended!

The TMC | ACT Accelerator has extended its program for applications through October 9, 2020. It is the only cancer therapeutics accelerator building relationships with health care professionals leading the world’s best cancer treatment programs at the Texas Medical Center member hospitals. The program is a CPRIT funded accelerator launched in collaboration with the Gulf Coast Consortium (GCC) and the University of Texas Medical Branch (UTMB) to support Texas-based biotech entrepreneurs and researchers.

ACT is a comprehensive nine-month program (January through September 2021) designed to enhance oncology biotech entrepreneurship training and drug development programs in Texas. ACT will provide Texas researchers and startups with integrated training, resources, and mentoring in order to advance innovative cancer therapy discoveries and development programs, ultimately leading to new approaches and therapies for cancer patients. For more information about the program, download flyer here or visit the TMC | ACT website for application and criteria.